Sign up USA
Proactive Investors - Run By Investors For Investors

Oppenheimer initiates coverage on ArQule with an Outperform rating and US$7 price target

Hartaj Singh expects the cancer specialist's two AKT inhibitors to each account for US$3 per share of ArQule's valuation
Cancerous growth
ArQule shares are trading lower in afternoon trade

Oppenheimer analyst Hartaj Singh is initiating coverage by tagging an Outperform rating and a US$7 price target on the cancer specialist ArQule (NASDAQ:ARQL), which has seen its shares rise close to fivefold since the year’s start.

Singh is bullish on ArQule’s competence in kinase inhibition, which plays an increasingly prominent role in the treatment of cancer. He argues that the “one-two punch of the company’s rare disease/oncology franchise in ARQ 092/751 (AKT inhibitors) and the blue-skies scenario of the reversible BTK-inhibitor ARQ 531 will create substantial value for shareholders over the near to mid-term.”

Singh expects the company's two cancer-fighting AKT inhibitors – ARQ092/751 and ARQ 531 to each account for $3 per share of ArQule’s valuation and says both therapies have about a 35% chance of making it to market.

ARQ092/751 is set to bring in sales of US$720m in 2027 while ARQ 531 looks ready to be the driver behind as much as US$730m worth of sales in 2026.

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and other rare diseases.

ArQule’s shares traded 2% lower at US$5.18 in late afternoon trade.

View full ARQL profile View Profile

ArQule Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use